PT - JOURNAL ARTICLE AU - Prakash, Ruchika S. AU - McKenna, Michael R. AU - Gbadeyan, Oyetunde AU - Shankar, Anita R. AU - Andridge, Rebecca AU - Scharre, Douglas W. TI - A Whole-Brain Functional Connectivity Model of Alzheimer’s Disease Pathology AID - 10.1101/2021.01.13.21249597 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.13.21249597 4099 - http://medrxiv.org/content/early/2021/01/21/2021.01.13.21249597.short 4100 - http://medrxiv.org/content/early/2021/01/21/2021.01.13.21249597.full AB - Early detection of Alzheimer’s disease (AD) is a necessity as prognosis is poor upon symptom onset. Although previous work diagnosing AD from protein-based biomarkers has been encouraging, cerebrospinal (CSF) biomarker measurement of AD proteins requires invasive lumbar puncture, whereas assessment of direct accumulation requires radioactive substance exposure in positron emission tomography (PET) imaging. Functional magnetic resonance imaging (fMRI)-based neuromarkers, offers an alternative, especially those built by capitalizing on variance distributed across the entire human connectome. In this study, we employed connectome-based predictive modeling (CPM) to build a model of functional connections that would predict CSF p-tau/Aβ42 (PATH-fc model) in individuals diagnosed with Mild Cognitive Impairment (MCI) and AD dementia. fMRI, CSF-based biomarker data, and longitudinal data from neuropsychological testing from the Alzheimer’s Disease NeuroImaging Initiative (ADNI) were utilized to build the PATH-fc model. Our results provide support for successful in-sample fit of the PATH-fc model in predicting AD pathology in MCI and AD dementia individuals. The PATH-fc model, distributed across all ten canonical networks, additionally predicted cognitive decline on composite measures of global cognition and executive functioning. Our highly distributed pathology-based model of functional connectivity disruptions had a striking overlap with the spatial affinities of amyloid and tau pathology, and included the default mode network as the hub of such network-based disruptions in AD. Future work validating this model in other external datasets, and to midlife adults and older adults with no known diagnosis, will critically extend this neuromarker development work using fMRI.Significance Statement Alzheimer’s disease (AD) is clinical-pathological syndrome with multi-domain amnestic symptoms considered the hallmark feature of the disease. However, accumulating evidence from autopsy studies evince support for the onset of pathophysiological processes well before the onset of symptoms. Although CSF- and PET-based biomarkers provide indirect and direct estimates of AD pathology, both methodologies are invasive. In here, we implemented a supervised machine learning algorithm – connectome-based predictive modeling – on fMRI data and found support for a whole-brain model of functional connectivity to predict AD pathology and decline in cognitive functioning over a two-year period. Our study provides support for AD pathology dependent functional connectivity disturbances in large-scale functional networks to influence the trajectory of key cognitive domains in MCI and AD patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project described in this publication was supported by Award Number UL1TR002733 from the National Center For Advancing Translational Sciences and Award Number R01AG054427 from the National Institute On Aging of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Advancing Translational Sciences, the National Institute on Aging or the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained approval to analyze de-identified data from the ADNI database (http://adni.loni.usc.edu). Thus, our study was exempt from local Institutional Review Board oversight. However, the ADNI study was approved by all Institutional Review Boards or Research Ethics Boards of all participating centers. All participants signed written informed consent at the time of enrollment. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe current study is a secondary analysis of publicly available data from The Alzheimer Disease Neuroimaging Initiative (ADNI). All data is publicly available.